What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Endometrial Cancer (2 trials)
- Main trialPhase 3
- “This is a Phase 3, multicenter, randomized, open-label trial to evaluate whether EG-007 plus Len+Pem is superior to Len+Pem alone in patients with advanced endometrial cancer (Stage III or IV). This trial will be preceded by a safety lead-in study with up to 28 patients (the safety lead-in is a separate, free-standing protocol). Approximately 450 patients will be randomized equally (1:1) to receive EG-007 plus Len+Pem or Len+Pem alone. The randomization will be stratified by the following stratification factors: * Diagnosis Classification (advanced Stage III/IV vs. recurrent endometrial…”In the company’s words, NCT05077215 on ClinicalTrials.gov
Other drugs for Advanced Endometrial Cancer
- PembrolizumabMerck & Co. · Phase 3
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- Puxitatug SamrotecanAstraZeneca · Phase 3
- RilvegostomigAstraZeneca · Phase 3
- Anlotinib HydrochlorideChia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
Coming up2
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Dec 2027 | Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer | |
| Phase 2Not yet recruiting | Mar 2027 | Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026